Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Combination drug therapy for combined hyperlipidemia.

¹Department of Medicine, Box 3510, Duke University Medical Center, Durham, NC 27710, USA.

Current Cardiology Reports

|September 12, 2000

Summary

Combination therapy for hyperlipidemia offers improved lipoprotein risk factors and potential atherothrombotic event prevention. Careful patient education on side effects and drug interactions is crucial for safe and effective treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Tandem mass spectrometric characterization of a specific cysteic acid residue in oxidized human apoprotein B-100.

Journal of the American Society for Mass Spectrometry·2013

Same author

Serum apolipoprotein C-III is independently associated with chronic hepatitis C infection and advanced fibrosis.

Hepatology international·2011

Same author

Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials.

Diabetes, obesity & metabolism·2011

Same author

Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome.

Diabetes, obesity & metabolism·2010

Same author

Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia.

Diabetes, obesity & metabolism·2009

Same author

Phospholipid hydrolytic enzymes in a 'cesspool' of arterial intimal lipoproteins: a mechanism for atherogenic lipid accumulation.

Arteriosclerosis, thrombosis, and vascular biology·2001

Area of Science:

Cardiology
Pharmacology
Metabolic Disorders

Background:

Combined hyperlipidemia poses significant cardiovascular risks.
Single-drug therapy may not fully address complex lipid profiles.
Combination therapies are increasingly explored for enhanced efficacy.

Purpose of the Study:

To review the advantages and safety of combination therapy for hyperlipidemia.
To evaluate the impact of combined drug regimens on lipoprotein risk factors and clinical outcomes.
To highlight the importance of patient education in managing combination therapy.

Main Methods:

Review of existing literature on combination therapies for hyperlipidemia.
Analysis of studies focusing on niacin-statins and fibrate-statins.
Assessment of safety profiles, including myopathy and rhabdomyolysis risks.
Consideration of other therapeutic combinations like fish oil, resins, and stanol esters.

Main Results:

Combination therapy can yield superior improvements in lipoprotein risk factors compared to monotherapy.
Certain combinations, like niacin-statins and fibrate-statins, show potential but carry risks of myopathy.
Lower statin doses and comprehensive patient education are key to mitigating safety concerns.
Non-statin combinations offer alternative strategies for lipid management.

Conclusions:

Combination therapy for hyperlipidemia, particularly combined forms, presents advantages in managing lipid profiles and preventing cardiovascular events.
Careful selection of drug combinations, appropriate dosing, and robust patient education are essential for optimizing safety and efficacy.
Further research into angiographic and clinical outcomes of specific combination regimens is warranted.

Related Experiment Videos